Skip to Content
Merck
  • Over 17-month complete clinical brain response with a well-tolerated lapatinib plus capecitabine combination in a very young patient afflicted by HER2-positive metastatic breast cancer.

Over 17-month complete clinical brain response with a well-tolerated lapatinib plus capecitabine combination in a very young patient afflicted by HER2-positive metastatic breast cancer.

Tumori (2014-02-08)
Valentina Sini, Antonello Menghi, Maria Concetta Cursano, Pier Luca Mandolini, Rosina Lanza
ABSTRACT

This report describes a case of ab initio metastatic HER2-positive breast cancer in a very young patient. The onset of breast cancer at such a young age is uncommon and could delay the diagnosis with unquestionable impact on the prognosis. Unfortunately, the patient experienced cerebral progression during first-line treatment. Indeed, brain metastases occur in about one-third of HER2-positive metastatic breast cancer patients during trastuzumab-based treatment. The small molecule lapatinib is active in established cerebral disease, and we report a complete brain response longer than expected, thanks to a well-tolerated, orally administered combination of lapatinib and capecitabine.

MATERIALS
Product Number
Brand
Product Description

Capecitabine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Capecitabine, ≥98% (HPLC)